Logo_Horizontal_Fill_White_Transparent.png
Neurona Therapeutics Announces Presentation of Updated Clinical Data at the Upcoming American Academy of Neurology (AAN) Annual Meeting from Lead Cell Therapy Candidate, NRTX-1001
07 mars 2024 16h00 HE | Neurona Therapeutics
Neurona Therapeutics to present updated clinical data from NRTX-1001 investigational cell therapy program at AAN Annual Meeting
Logo_Horizontal_Fill_White_Transparent.png
Neurona Therapeutics Raises $120M to Advance Groundbreaking Pipeline of Regenerative Cell Therapy Candidates for Chronic Neurological Disorders
08 févr. 2024 08h00 HE | Neurona Therapeutics
$120M financing will support advancement of ground-breaking regenerative cell therapies for chronic CNS disorders
Synlogic_Logo_Blue.png
Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria
02 févr. 2024 12h00 HE | Synlogic, Inc.
Findings support positive proof of mechanism, through successful degradation of methionine, precursor to homocysteine, using dietary disease model in preclinical models and healthy volunteer study ...
22157.jpg
Healthcare Clinical Analytics Market - Global Industry Analysis and Forecast 2031 - Market Set for Strong Growth Fueled by High Adoption Rates and Technological Advancements
30 janv. 2024 13h35 HE | Research and Markets
Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The "Healthcare Clinical Analytics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade,...
Global Clinical Data Analytics Market
Global Clinical Data Analytics Market Forecast 2024-2030: Increasing volume of unstructured healthcare data and demand for real-time insights
22 janv. 2024 08h28 HE | Research and Markets
Dublin, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The "Global Clinical Data Analytics Market by Component (Hardware, Services, Software), Type (Descriptive, Predictive, Prescriptive), Application, End-User...
selectION, Inc. to Present Update on Clinical Progress at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on January 11, 2024
05 janv. 2024 04h00 HE | AKAMPION
Best-in-class Kv1.3 blocker has successfully completed a Phase 1b trial in atopic dermatitis patientsPipeline molecule to treat T cell mediated autoimmune diseases San Diego, CA, USA, and...
Mendus_Red.png
Mendus presenterar positiva överlevnadsdata från fas 2-studien ADVANCE II som utvärderar vididencel som underhållsbehandling vid AML vid ASH-konferensen
11 déc. 2023 13h30 HE | Mendus AB
Pressmeddelande Stockholm, 11 december 2023 Per den 24 november 2023 var återfallsfri medianöverlevnad (mRFS) 30,4 månader Medianen för totalöverlevnad (mOS) hade inte ännu inte uppnåtts, med...
Mendus_Red.png
Mendus announces positive survival data from Phase 2 ADVANCE II trial evaluating vididencel as maintenance therapy for AML at ASH 2023
11 déc. 2023 13h30 HE | Mendus AB
Press Release Stockholm, Sweden, December 11, 2023 As of November 24, 2023, median relapse-free survival (mRFS) stood at 30.4 months Median overall survival (mOS) was not reached, with the...
qcentrix_color_RGB.jpg
Q-Centrix Launches the Research Network to Expand the Impact of Clinical Data by Connecting Hospitals and Life Sciences Organizations
14 nov. 2023 08h00 HE | Q-Centrix
The platform builds upon Q-Centrix’s ethos that data management is critical to expanding clinical research and trials
logo.jpg
ImCheck Presented Updated Positive Data from Phase I/IIa EVICTION-2 Trial of ICT01 in Combination with Low-dose IL-2 at SITC 2023
03 nov. 2023 14h00 HE | ImCheck Therapeutics SAS
ImCheck Presented Updated Positive Data from Phase I/IIa EVICTION-2 Trial of ICT01 in Combination with Low-dose IL-2 at SITC 2023 Interim data from EVICTION-2 study confirms safety and tolerability...